Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma.

Yusuf, R Z; Dey, B; Yeap, B Y; McAfee, S; Attar, E; Sepe, P S; Dube, C; Spitzer, T R; Ballen, K K

Yusuf, R Z; Dey, B; Yeap, B Y; McAfee, S; Attar, E; Sepe, P S; Dube, C; Spitzer, T R; Ballen, K K.

Affiliation

Yusuf RZ; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Bone Marrow Transplant ; 43(1): 37-42, 2009 Jan.

Article in En | MEDLINE | ID: mdl-18794868

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Hematopoietic Stem Cell Transplantation; Lymphoma, Non-Hodgkin/therapy; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Busulfan/administration & dosage; Busulfan/adverse effects; Combined Modality Therapy; Cyclophosphamide/administration & dosage; Cyclophosphamide/adverse effects; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin/drug therapy; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Transplantation Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google